person · Reporting owner

HENDERSON MICHAEL THOMAS

Disclosed activity across 4 companies

Tapewire entity: 1951
SEC CIK: 0001779990

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BridgeBio Pharma, Inc.BBIO · Entity 3360	Chief Business Officer	December 15, 2020	December 17, 2020
Spyre Therapeutics, Inc.SYRE · Entity 2649	Director	June 22, 2026	June 24, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BridgeBio Pharma, Inc.

Report date December 15, 2020 · Filed December 17, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.07 · Expires 2030-04-01	Direct	4,456	Reported balance After 2020-12-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-12-15 · Grant · Acquired 4,456 · Balance 4,456 F1: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. F2: 1,671 shares subject to the stock option were vested as of the date of acquisition, 93 shares shall vest on January 1, 2021, and 2,692 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.07 · Expires 2030-07-20	Direct	3,137	Reported balance After 2020-12-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-12-15 · Grant · Acquired 3,137 · Balance 3,137 F1: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. F3: 1,177 shares subject to the stock option were vested as of the date of acquisition, 65 shares shall vest on January 1, 2021, and 1,895 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.80 · Expires 2030-09-29	Direct	2,199	Reported balance After 2020-12-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-12-15 · Grant · Acquired 2,199 · Balance 2,199 F1: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. F4: 825 shares subject to the stock option were vested as of the date of acquisition, 46 shares shall vest on January 1, 2021, and 1,328 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.

Filing footnotes · ownership attribution and instrument terms

F1: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio.

F2: 1,671 shares subject to the stock option were vested as of the date of acquisition, 93 shares shall vest on January 1, 2021, and 2,692 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.

F3: 1,177 shares subject to the stock option were vested as of the date of acquisition, 65 shares shall vest on January 1, 2021, and 1,895 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.

F4: 825 shares subject to the stock option were vested as of the date of acquisition, 46 shares shall vest on January 1, 2021, and 1,328 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.

Spyre Therapeutics, Inc.

Report date June 22, 2026 · Filed June 24, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	68,606	Reported balance After 2026-06-22 transaction · row 1 1 source row Row 1 · 2026-06-22 · Sale · Disposed 20,000 · Balance 68,606 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARYA Sciences Acquisition Corp IV

Report date July 31, 2024 · Filed August 01, 2024

Section 16 reporting ended · disclosed 2024-08-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B ordinary sharesSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2024-07-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-07-31 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share, on a one-for-one basis.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share, on a one-for-one basis.

Apogee Therapeutics, Inc.

Report date September 03, 2026 · Filed September 03, 2026

Section 16 reporting ended · disclosed 2026-09-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-09-03 transaction · row 1 1 source row Row 1 · 2026-09-03 · Disposition to issuer · Disposed 920,941 · Balance 0 F1: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.86 · Expires 2033-12-18	Direct	Reported balance After 2026-09-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-09-03 · Disposition to issuer · Disposed 387,012 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.07 · Expires 2034-12-09	Direct	Reported balance After 2026-09-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-09-03 · Disposition to issuer · Disposed 357,036 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.78 · Expires 2036-01-02	Direct	Reported balance After 2026-09-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-09-03 · Disposition to issuer · Disposed 253,016 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc.

F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.

F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 03, 2026 Filed Sep 3, 2026 20:39 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	Disposition to issuerStock Option (Right to Buy) · Derivative	253,016	Not disclosed Strike: $75.78	Not disclosed	Disclosure SEC source: 0001140361-26-035609 · form4.xml · derivative · entry 4 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 253,016 shares Expires 2036-01-02 F3 · price: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2 · derivative.exercise_date: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. F3 · derivative.exercise_date: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. Read SEC document
September 03, 2026 Filed Sep 3, 2026 20:39 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	Disposition to issuerStock Option (Right to Buy) · Derivative	357,036	Not disclosed Strike: $49.07	Not disclosed	Disclosure SEC source: 0001140361-26-035609 · form4.xml · derivative · entry 3 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 357,036 shares Expires 2034-12-09 F3 · price: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2 · derivative.exercise_date: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. F3 · derivative.exercise_date: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. Read SEC document
September 03, 2026 Filed Sep 3, 2026 20:39 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	Disposition to issuerStock Option (Right to Buy) · Derivative	387,012	Not disclosed Strike: $22.86	Not disclosed	Disclosure SEC source: 0001140361-26-035609 · form4.xml · derivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 387,012 shares Expires 2033-12-18 F3 · price: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2 · derivative.exercise_date: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. F3 · derivative.exercise_date: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. Read SEC document
September 03, 2026 Filed Sep 3, 2026 20:39 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	Disposition to issuerCommon Stock	920,941	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-26-035609 · form4.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. F1 · price: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. Read SEC document
July 10, 2026 Filed Jul 10, 2026 20:00 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	GiftCommon Stock	75,046	$0.00	$0.00	Disclosure SEC source: 0001104659-26-082758 · tm2620107-1_4seq1.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 920,941 F3 · kind: This transaction involves a bona fide gift of securities from the reporting person to a donor advised fund. Read SEC document
July 08, 2026 Filed Jul 10, 2026 20:00 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	20,000	$133.63	$2,672,600.00	Disclosure SEC source: 0001104659-26-082758 · tm2620107-1_4seq1.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 995,987 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $133.52 to $133.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
June 22, 2026 Filed Jun 24, 2026 01:32 UTC	Spyre Therapeutics, Inc. SYRE · Entity 2649	SaleCommon Stock	20,000	$100.00	$2,000,000.00	Disclosure SEC source: 0001636282-26-000084 · wk-form4_1782264740.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,606 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026. Read SEC document
June 22, 2026 Filed Jun 25, 2026 00:00 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	80,000	$132.54	$10,603,200.00	Disclosure SEC source: 0001104659-26-077426 · tm2618514-2_4seq1.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,015,987 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $132.50 to $132.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
June 10, 2026 Filed Jun 12, 2026 21:05 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	614	$86.89	$53,350.46	Disclosure SEC source: 0001104659-26-073567 · tm2617750-1_4seq1.xml · nonDerivative · entry 6 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,095,987 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F7 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.835 to $87.165, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
June 10, 2026 Filed Jun 12, 2026 21:05 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	2,305	$86.27	$198,852.35	Disclosure SEC source: 0001104659-26-073567 · tm2617750-1_4seq1.xml · nonDerivative · entry 5 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,096,601 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F6 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.74 to $86.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
June 10, 2026 Filed Jun 12, 2026 21:05 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	1,577	$85.19	$134,344.63	Disclosure SEC source: 0001104659-26-073567 · tm2617750-1_4seq1.xml · nonDerivative · entry 4 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,098,906 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F5 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $84.71 to $85.665, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
June 10, 2026 Filed Jun 12, 2026 21:05 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	1,080	$84.18	$90,914.40	Disclosure SEC source: 0001104659-26-073567 · tm2617750-1_4seq1.xml · nonDerivative · entry 3 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,100,483 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.595 to $84.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
June 10, 2026 Filed Jun 12, 2026 21:05 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	7,654	$82.78	$633,598.12	Disclosure SEC source: 0001104659-26-073567 · tm2617750-1_4seq1.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,101,563 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.57 to $83.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
June 10, 2026 Filed Jun 12, 2026 21:05 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	6,770	$82.21	$556,561.70	Disclosure SEC source: 0001104659-26-073567 · tm2617750-1_4seq1.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,109,217 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.57 to $82.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
May 27, 2026 Filed May 29, 2026 21:55 UTC	Spyre Therapeutics, Inc. SYRE · Entity 2649	GrantStock Option (Right to Buy) · Derivative	8,026	$0.00 Strike: $72.51	$0.00	Disclosure SEC source: 0001636282-26-000067 · wk-form4_1780091744.xml · derivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,026 Underlying: Common Stock · 8,026 shares Expires 2036-05-27 F1 · derivative.exercise_date: This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date. Read SEC document
May 13, 2026 Filed May 16, 2026 00:00 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	1,341	$82.58	$110,739.78	Disclosure SEC source: 0001104659-26-062867 · tm2614621-1_4seq1.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,115,987 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.470 to $83.265, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
May 13, 2026 Filed May 16, 2026 00:00 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	18,659	$82.05	$1,530,970.95	Disclosure SEC source: 0001104659-26-062867 · tm2614621-1_4seq1.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,117,328 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.455 to $82.440, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
May 08, 2026 Filed May 9, 2026 01:31 UTC	Spyre Therapeutics, Inc. SYRE · Entity 2649	SaleCommon Stock	19,269	$75.35	$1,451,919.15	Disclosure SEC source: 0001636282-26-000053 · wk-form4_1778290306.xml · nonDerivative · entry 4 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,606 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026. F5 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $75.15 to $75.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
May 08, 2026 Filed May 9, 2026 01:31 UTC	Spyre Therapeutics, Inc. SYRE · Entity 2649	SaleCommon Stock	24,814	$74.76	$1,855,094.64	Disclosure SEC source: 0001636282-26-000053 · wk-form4_1778290306.xml · nonDerivative · entry 3 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,875 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.15 to $75.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
May 08, 2026 Filed May 9, 2026 01:31 UTC	Spyre Therapeutics, Inc. SYRE · Entity 2649	SaleCommon Stock	33,513	$73.72	$2,470,578.36	Disclosure SEC source: 0001636282-26-000053 · wk-form4_1778290306.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,689 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.15 to $74.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
May 08, 2026 Filed May 9, 2026 01:31 UTC	Spyre Therapeutics, Inc. SYRE · Entity 2649	SaleCommon Stock	2,404	$72.57	$174,458.28	Disclosure SEC source: 0001636282-26-000053 · wk-form4_1778290306.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 166,202 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $72.03 to $73.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
April 16, 2026 Filed Apr 20, 2026 20:05 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	Exercise / conversionStock Option (Right to Buy) · Derivative	3,000	$0.00 Strike: $22.86	$0.00	Disclosure SEC source: 0001104659-26-045482 · tm2612090-2_4seq1.xml · derivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 387,012 Underlying: Common Stock · 3,000 shares Expires 2033-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option represents the right to purchase 398,512 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer. Read SEC document
April 16, 2026 Filed Apr 20, 2026 20:05 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	Exercise / conversionCommon Stock	3,000	$22.86	$68,580.00	Disclosure SEC source: 0001104659-26-045482 · tm2612090-2_4seq1.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,135,987 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 08, 2026 Filed Apr 11, 2026 00:00 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	200	$85.00	$17,000.00	Disclosure SEC source: 0001104659-26-042155 · tm2611503-1_4seq1.xml · nonDerivative · entry 3 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,132,987 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. Read SEC document
April 08, 2026 Filed Apr 11, 2026 00:00 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	2,000	$83.26	$166,520.00	Disclosure SEC source: 0001104659-26-042155 · tm2611503-1_4seq1.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,133,187 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.00 to $83.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
April 08, 2026 Filed Apr 11, 2026 00:00 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	17,800	$82.48	$1,468,144.00	Disclosure SEC source: 0001104659-26-042155 · tm2611503-1_4seq1.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,135,187 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.00 to $82.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
March 11, 2026 Filed Mar 14, 2026 00:00 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	3,418	$75.86	$259,289.48	Disclosure SEC source: 0001104659-26-027802 · tm268769-1_4seq1.xml · nonDerivative · entry 3 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,152,987 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $75.585 to $76.480, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
March 11, 2026 Filed Mar 14, 2026 00:00 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	8,219	$74.83	$615,027.77	Disclosure SEC source: 0001104659-26-027802 · tm268769-1_4seq1.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,156,405 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.525 to $75.400, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
March 11, 2026 Filed Mar 14, 2026 00:00 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	8,363	$74.29	$621,287.27	Disclosure SEC source: 0001104659-26-027802 · tm268769-1_4seq1.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,164,624 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.525 to $74.520, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
February 11, 2026 Filed Feb 14, 2026 01:00 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	955	$64.99	$62,065.45	Disclosure SEC source: 0001104659-26-015453 · tm266326-1_4seq1.xml · nonDerivative · entry 3 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,172,987 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.95 to $65.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
February 11, 2026 Filed Feb 14, 2026 01:00 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	7,551	$63.73	$481,225.23	Disclosure SEC source: 0001104659-26-015453 · tm266326-1_4seq1.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,173,942 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.33 to $64.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
February 11, 2026 Filed Feb 14, 2026 01:00 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	11,494	$62.96	$723,662.24	Disclosure SEC source: 0001104659-26-015453 · tm266326-1_4seq1.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,181,493 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.33 to $63.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
January 21, 2026 Filed Jan 24, 2026 02:31 UTC	Spyre Therapeutics, Inc. SYRE · Entity 2649	OtherCommon Stock	63,227	$0.00	$0.00	Disclosure SEC source: 0001779990-26-000002 · wk-form4_1769221869.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,606 F1 · kind: Represents the pro-rata distribution of shares of common stock for no consideration from a limited liability company in which the Reporting Person is a member. Read SEC document
January 14, 2026 Filed Jan 17, 2026 01:00 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	470	$83.79	$39,381.30	Disclosure SEC source: 0001104659-26-004659 · tm263357-1_4seq1.xml · nonDerivative · entry 6 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,192,987 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F7 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.73 to $83.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
January 14, 2026 Filed Jan 17, 2026 01:00 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	5,386	$83.16	$447,899.76	Disclosure SEC source: 0001104659-26-004659 · tm263357-1_4seq1.xml · nonDerivative · entry 5 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,193,457 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F6 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.71 to $83.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
January 14, 2026 Filed Jan 17, 2026 01:00 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	1,854	$82.41	$152,788.14	Disclosure SEC source: 0001104659-26-004659 · tm263357-1_4seq1.xml · nonDerivative · entry 4 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,198,843 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F5 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.70 to $82.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
January 14, 2026 Filed Jan 17, 2026 01:00 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	2,374	$81.00	$192,294.00	Disclosure SEC source: 0001104659-26-004659 · tm263357-1_4seq1.xml · nonDerivative · entry 3 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,200,697 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.69 to $81.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
January 14, 2026 Filed Jan 17, 2026 01:00 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	8,476	$79.82	$676,554.32	Disclosure SEC source: 0001104659-26-004659 · tm263357-1_4seq1.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,203,071 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $79.28 to $80.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
January 14, 2026 Filed Jan 17, 2026 01:00 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	1,440	$78.64	$113,241.60	Disclosure SEC source: 0001104659-26-004659 · tm263357-1_4seq1.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,211,547 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $78.16 to $79.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
January 02, 2026 Filed Jan 7, 2026 01:01 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	GrantStock Option (Right to Buy) · Derivative	253,016	$0.00 Strike: $75.78	$0.00	Disclosure SEC source: 0001104659-26-001484 · tm261906-3_4seq1.xml · derivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253,016 Underlying: Common Stock · 253,016 shares Expires 2036-01-02 F1 · derivative.exercise_date: This option represents the right to purchase 253,016 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer. Read SEC document
December 10, 2025 Filed Dec 13, 2025 01:00 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	560	$76.58	$42,884.80	Disclosure SEC source: 0001104659-25-120758 · tm2533301-1_4seq1.xml · nonDerivative · entry 3 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,212,987 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. Read SEC document
December 10, 2025 Filed Dec 13, 2025 01:00 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	10,005	$75.79	$758,278.95	Disclosure SEC source: 0001104659-25-120758 · tm2533301-1_4seq1.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,213,547 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $75.30 to $76.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
December 10, 2025 Filed Dec 13, 2025 01:00 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	9,435	$74.88	$706,492.80	Disclosure SEC source: 0001104659-25-120758 · tm2533301-1_4seq1.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,223,552 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.30 to $75.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
December 04, 2025 Filed Dec 6, 2025 01:00 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	40,000	$75.01	$3,000,400.00	Disclosure SEC source: 0001104659-25-118983 · tm2532835-1_4seq1.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,232,987 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $75.00 to $75.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
November 13, 2025 Filed Nov 14, 2025 01:24 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	100	$64.52	$6,452.00	Disclosure SEC source: 0001104659-25-111626 · tm2531267-1_4seq1.xml · nonDerivative · entry 4 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,272,987 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. Read SEC document
November 13, 2025 Filed Nov 14, 2025 01:24 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	1,786	$63.89	$114,107.54	Disclosure SEC source: 0001104659-25-111626 · tm2531267-1_4seq1.xml · nonDerivative · entry 3 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,273,087 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.52 to $64.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
November 13, 2025 Filed Nov 14, 2025 01:24 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	14,774	$63.14	$932,830.36	Disclosure SEC source: 0001104659-25-111626 · tm2531267-1_4seq1.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,274,873 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.50 to $63.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
November 13, 2025 Filed Nov 14, 2025 01:24 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	3,340	$61.93	$206,846.20	Disclosure SEC source: 0001104659-25-111626 · tm2531267-1_4seq1.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,289,647 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.45 to $62.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
May 29, 2025 Filed Jun 2, 2025 20:35 UTC	Spyre Therapeutics, Inc. SYRE · Entity 2649	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $15.55	$0.00	Disclosure SEC source: 0001636282-25-000065 · wk-form4_1748896522.xml · derivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-05-29 F1 · derivative.exercise_date: This option represents a right to purchase 25,000 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 29, 2025 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document
March 05, 2025 Filed Mar 8, 2025 01:01 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	2,674	$30.62	$81,877.88	Disclosure SEC source: 0001104659-25-021861 · tm258443-2_4seq1.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,292,987 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.52 to $30.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.